LightOx Ltd, a company developing novel therapeutic treatments including light activated chemotherapy for early-stage oral cancer, has appointed Dr Natalie Young as Senior Research Scientist.
Natalie’s appointment supports their goal of bringing their revolutionary mouth cancer and anti-microbial treatments to market, expanding the team to 12.
She brings with her a wealth of experience across the field of biomolecular science in both academic and industrial sectors. Having worked on in-vitro (cells) and in-vivo (animal) models of disease and experience in lab management. At LightOx Natalie will play a key role in the development of their lead candidate LXD191 to treat mouth cancer as well as supporting their antimicrobial work.
Dr Sam Whitehouse, Chief Executive Officer at LightOx said;
“I am delighted to welcome Natalie to the team. With her strong biological background, she brings with her a wealth of experience. Natalie first started working with our team during her Postdoctoral Research Associate role at Durham University in 2021 and it’s great now to be able to offer her a full-time role in the company. I know she will be a real asset, and we wish her all the best.”
Dr Natalie Young, Senior Research Scientist at LightOx said;
“It’s wonderful to be joining the LightOx team. I’ve always admired their work and mission to bring their revolutionary mouth cancer drug to market. Something I was able to see firsthand during my Postdoctoral Research Associate role. And to now be offered a full-time role with the company is incredible. I’m really looking forward to working with the team and supporting their key projects through the contribution of my skills and experience for such an important cause.”
